Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
The Oncologist|June 12, 2025
Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapyFlavia Jacobs, Mariangela Gaudio, Chiara Andreottola, et al.
The Oncologist|January 11, 2026
Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitorsRosalba Torrisi, Federica Giugliano, Laura Giordano, et al.
Digital Health|November 6, 2024
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systemsFlavia Jacobs, Saverio D'Amico, Elena Zazzetti, et al.
Breast (Edinburgh, Scotland)|March 31, 2023
Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patientsDamiano Gentile, Andrea Sagona, Camilla De Carlo, et al.
Tumori|July 31, 2026
Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancerChiara Benvenuti, Alessandro Viansone, Flavia Jacobs, et al.
JCO Clinical Cancer Informatics|November 6, 2025
Longitudinal Synthetic Data Generation by Artificial Intelligence to Accelerate Clinical and Translational Research in Breast CancerElena Zazzetti, Saverio D'Amico, Flavia Jacobs, et al.
Critical Reviews in Oncology/Hematology|August 10, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabVeronique Debien, Guilherme Nader Marta, Elisa Agostinetto, et al.
Cancer Treatment Reviews|June 3, 2026
Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomesFlavia Jacobs, Alessio Polymeropoulos, Matteo De Monte, et al.
Tumori|December 15, 2025
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switchingMariangela Gaudio, Anna Floreani, Greta Schivardi, et al.
Clinical Breast Cancer|June 7, 2025
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International StudySoraia Lobo-Martins, Veronique Debien, Elisa Agostinetto, et al.
Pageof 5